Form 4 Filing for BioXcel Therapeutics, Inc. - Officer Transaction

This filing details a transaction by Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, Inc. On June 15, 2026, Mr. Yocca was involved in a transaction concerning 35 shares of Common Stock, acquired under a grant of Restricted Stock Units (RSUs). The RSUs, granted on March 15, 2023, vest over time, with 25% vesting on the first anniversary of the grant date and subsequent 6.25% vesting every three months thereafter, contingent upon continued employment. The reported transaction code is "M", indicating a "missed" event, and the shares were acquired ("A"). Post-transaction, Mr. Yocca holds 26,210 shares of Common Stock directly. Additionally, the filing reports a disposal of 35 RSUs, which represent a contingent right to receive one share of Common Stock each, with the post-transaction holding of RSUs being 212.